Defined solutions for cell cultures. relative genom ic titer Xell's AAV2 titer boost
Teamwork makes the Commercial reference
project work: Xell's HEK ViP NX
4.0
Xell’s HEK Media Bundle 3.5
3.0
Identify the most suitable HEK growth and 2.5
transfection media: 2.0
1.5
For HEK293 and other human cell lines 1.0
0.5
100% chemically defined and animal-origin free 0.0
HEK cell line 1 HEK cell line 2
All-in-one solutions: thawing, transfection/
infection and production
Suitable and Scalable: from R&D to large-scale
GMP production
Optimized for virus/viral vector production
(e.g., AAV, lentivirus)
Xell AG (Headquarters) RRR Labs Pvt Ltd (Distributor)
Bielefeld, Germany www.xell.de Mumbai, India www.rrrlabs.com
+49 521 96989 200 [email protected] +91 22 2783 3655 [email protected]
RNI No. DELENG/2004/13061 Published on 28th of previous month PCW/193/2020-2022
Posting Date: 30th of every month Posted at Ex Servicemen Colony PO, Pune-38
Why Choose
Corning Fetal
Bovine Serum?
Corning high-quality
fetal bovine serum
products complement
our wide range of
sterile, low endotoxin
classical cell culture
media perfectly.
Origin Statement
We offer several premium FBS (Fetal Bovine Serum) products collected in approved abattoirs from herds in the
United States. Also, our regular FBS (Fetal Bovine Serum) is collected in approved facilities from herds located in
countries approved by the USDA for importation into the United States. In certain regions we also provide South
America-sourced FBS (Fetal Bovine Serum) manufactured at facilities approved by the appropriate local authorities.
Sera Processing ISIA Traceability Certified
Corning Life Sciences has been traceability
certified according to the International Serum
Industry Association (ISIA) Traceability Program.
EDQM Certificates of Suitability
Fetal Bovine Serum, United States Origin
This product has been granted a Certificate of
Suitability, R0-CEP 2018-271, by the European
Directorate for the Quality of Medicines
(EDQM) certifying that the product meets the
criteria described in the current version of the
monograph no. 1483 of the European
Pharmacopoeia “Product with risk of
transmitting agent of animal spongiform
encephalopathies.”
Stay tuned for more update about our
FBS offering!
India [email protected]
t 91 124 4604000
f 91 124 4604099
The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
GUNG-HOPHARMA R&DINVESTMENTSSURPASS $3B
While the pharmaceutical industry helped combatCOVID-19, from R&D actions on potential treatmentstrategies to balancing the medicines supply chainin the time of crisis, it struggled to maintain thenatural market flow. As a result, many pharmacompanies had to abort some of their ongoing R&Dinvestment plans. However for FY20-21, the averageR&D expenses constituted 7.2 per cent of the totalrevenues of the pharma companies, with Lupin,Alembic Pharma and Dr. Reddy’s spending morethan others. The cumulative R&D expenditure of theleading 10 pharma companies has been around Rs10,627 crore ($1.43 billion) in the previous fiscal. Thisfigure eventually reaches an approximate amountof Rs 22,500 crore ($3.03 billion) after consideringthe cumulative expenditure by other small andmedium players of the India pharma industry
Discover the best professional documents and content resources in AnyFlip Document Base.
Search